Stay updated on Satralizumab in Generalized Myasthenia Gravis Clinical Trial
Sign up to get notified when there's something new on the Satralizumab in Generalized Myasthenia Gravis Clinical Trial page.

Latest updates to the Satralizumab in Generalized Myasthenia Gravis Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe study page's revision label was updated from v3.6.3 to v3.6.4, signaling a new version of the record.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedA new revision entry v3.6.3 has been added in the Study Documents, replacing the previous v3.6.2. This reflects an updated version of the study protocol/document set associated with the study.SummaryDifference0.0%

- Check39 days agoChange DetectedThe page's revision indicator was updated to v3.6.2, replacing v3.6.0. This is a metadata update and does not alter trial details, eligibility criteria, or user-facing content.SummaryDifference0.0%

- Check54 days agoChange DetectedThe page adds guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) and a prominent 'No longer looking for participants' notice to reflect halted recruitment; it also updates the header styling to 'Intervention/Treatment' with a revised version tag to v3.6.0, replacing the previous 'Intervention / Treatment' header and the 'Revision: v3.5.5' entry.SummaryDifference0.3%

- Check61 days agoChange DetectedThe page shows a new revision identifier (v3.5.5) replacing the previous v3.5.4, indicating an behind-the-scenes update to the page's version.SummaryDifference0.0%

- Check82 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4 on the Study Details page, indicating a content update. This appears to be a minor metadata change with no evident alterations to trial data or eligibility criteria.SummaryDifference0.0%

Stay in the know with updates to Satralizumab in Generalized Myasthenia Gravis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Satralizumab in Generalized Myasthenia Gravis Clinical Trial page.